Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

Marina Cazzaniga,Laura Cortesi,A. Ferzi,L. Scaltriti,Federica Cicchiello,Mariangela Ciccarese,S. Della Torre,F. Villa,M. Giordano,Claudio Verusio,M. Nicolini,Anna Gambaro,L. Zanlorenzi,E. Biraghi,L. Legramandi,E Rulli

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

2016

Marina Cazzaniga
Laura Cortesi
A. Ferzi
L. Scaltriti
Federica Cicchiello
Mariangela Ciccarese
S. Della Torre
F. Villa
M. Giordano
Claudio Verusio
M. Nicolini
Anna Gambaro
L. Zanlorenzi
E. Biraghi
L. Legramandi
E Rulli

Purpose The VICTOR-1 study demonstrated that the all-oral metronomic combination of vinorelbine and capecitabine is highly active and well tolerated in hormone receptor-positive/HER2-negative patients. The VICTOR-2 study was designed to confirm these results.

Keywords:

Breast cancer
Capecitabine
Disease
HER2 negative
Vinorelbine
Metronomic Chemotherapy
Oncology
Internal medicine
Medicine
disease control

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations